Hamamatsu Medical Imaging Center, Hamamatsu Medical Photonics Foundation, 5000 Hirakuchi, Hamakita-ku, Hamamatsu, Shizuoka, 434-0041, Japan.
Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation, 1-5-4 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
Ann Nucl Med. 2020 May;34(5):358-368. doi: 10.1007/s12149-020-01456-9. Epub 2020 Mar 21.
To prospectively evaluate the value of whole-body cancer screening with multiple modalities including FDG-PET in a healthy population.
The study was conducted in 1197 healthy individuals aged ≥ 35 years at enrollment between August 2003 and July 2004. All participants were scheduled to receive annual whole-body cancer screening five times (screening period) with subsequent long-term follow-up (follow-up period). The endpoints of the study were definitive cancer diagnosis, cancer-related death, and all-cause death.
The follow-up rate was 99.8% for the screening period and 96.2% for the follow-up period. Forty-five cancers were confirmed during the screening period (August 2003 to July 2009), and 37 of the 45 were detected by the screening. Fourteen of the 45 were PET positive. Sixteen, 5, 4, 9 and 11 cancers were confirmed after the first, the second, the third, the fourth, and the fifth (took 2 years) screening, respectively. Eight participants died, of whom five died of cancer. The rate of cancer incidence (per 100,000) of 628.7 (95% confidence interval [CI] 445.0-812.4) was significantly high, and the rates of cancer mortality and all-cause mortality of 69.9 (95% CI 8.6-131.1) and 111.8 (95% CI 34.3-189.2), respectively, were significantly low, compared with the corresponding rates of 379.3, 138.2 and 354.2, respectively, in the age-rank- and sex-matched general population. During the follow-up period (August 2009 to July 2013), 37 cancers were confirmed and 30 of the 37 were detected. Seven participants died, of whom three died of cancer. The rate of cancer incidence was 809.6 (95% CI 548.7-1070.5). The rates of cancer mortality and all-cause mortality of 65.6 (95% CI 0-139.9) and 153.2 (95% CI 39.7-266.6), respectively, were significantly low compared with 190.1 and 462.3, respectively, in the general population.
Cancer detection by PET alone was limited. While the high cancer incidence was attributed to the extensive screening, the low cancer and all-cause mortality may indicate the potential value of this type of cancer screening. Cancer incidence increases with aging and it has been shown that continuous screening may reduce the risk caused by the cancer progression.
前瞻性评估包括 FDG-PET 在内的多种方法进行全身癌症筛查在健康人群中的价值。
这项研究纳入了 2003 年 8 月至 2004 年 7 月期间年龄≥35 岁的 1197 名健康个体。所有参与者均计划在 5 年内(筛查期)每年进行一次全身癌症筛查,并随后进行长期随访(随访期)。研究的终点是明确的癌症诊断、癌症相关死亡和全因死亡。
筛查期的随访率为 99.8%,随访期的随访率为 96.2%。在筛查期(2003 年 8 月至 2009 年 7 月)内确诊了 45 例癌症,其中 37 例通过筛查发现。这 45 例中有 14 例为 PET 阳性。16、5、4、9 和 11 例癌症分别在首次、第二次、第三次、第四次和第五次(历时 2 年)筛查后确诊。有 8 名参与者死亡,其中 5 人死于癌症。癌症发病率(每 10 万人)为 628.7(95%置信区间 [CI]:445.0-812.4),明显较高,癌症死亡率和全因死亡率分别为 69.9(95% CI:8.6-131.1)和 111.8(95% CI:34.3-189.2),明显较低,而年龄匹配和性别匹配的普通人群的相应发病率分别为 379.3、138.2 和 354.2。在随访期(2009 年 8 月至 2013 年 7 月)内,共确诊了 37 例癌症,其中 30 例通过筛查发现。有 7 名参与者死亡,其中 3 人死于癌症。癌症发病率为 809.6(95% CI:548.7-1070.5)。癌症死亡率和全因死亡率分别为 65.6(95% CI:0-139.9)和 153.2(95% CI:39.7-266.6),明显较低,而普通人群的相应死亡率分别为 190.1 和 462.3。
仅通过 PET 进行癌症检测是有限的。虽然高癌症发病率归因于广泛的筛查,但低癌症和全因死亡率可能表明这种类型的癌症筛查具有潜在价值。癌症发病率随年龄增长而增加,已经表明连续筛查可能降低癌症进展带来的风险。